| Literature DB >> 35049859 |
Joko Tri Wibowo1, Peni Ahmadi1, Siti Irma Rahmawati1, Asep Bayu1, Masteria Yunovilsa Putra1, Anake Kijjoa2.
Abstract
Novel secondary metabolites from marine macroorganisms and marine-derived microorganisms have been intensively investigated in the last few decades. Several classes of compounds, especially indole alkaloids, have been a target for evaluating biological and pharmacological activities. As one of the most promising classes of compounds, indole alkaloids possess not only intriguing structural features but also a wide range of biological/pharmacological activities including antimicrobial, anti-inflammatory, anticancer, antidiabetic, and antiparasitic activities. This review reports the indole alkaloids isolated during the period of 2016-2021 and their relevant biological/pharmacological activities. The marine-derived indole alkaloids reported from 2016 to 2021 were collected from various scientific databases. A total of 186 indole alkaloids from various marine organisms including fungi, bacteria, sponges, bryozoans, mangroves, and algae, are described. Despite the described bioactivities, further evaluation including their mechanisms of action and biological targets is needed to determine which of these indole alkaloids are worth studying to obtain lead compounds for the development of new drugs.Entities:
Keywords: bioactive compounds; indole alkaloids; marine natural products; marine sponges; marine-derived fungi
Mesh:
Substances:
Year: 2021 PMID: 35049859 PMCID: PMC8781670 DOI: 10.3390/md20010003
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Classification of indole alkaloids based on chemical structures.
Figure 2Distribution of the marine-derived indole alkaloids isolated from source organisms from January 2016 to October 2021.
Figure 3Structures of 1–8.
Figure 4Structures of 9–23.
Figure 5Structures of 24–33.
Figure 6Structures of 34–49.
Figure 7Structures of 50–62.
Figure 8(a) Proposed biosynthetic pathways of 50, 52, and 53 from paxilline (I); (b) Proposed biosynthetic pathways to 51 from emindole SB (VI).
Figure 9Structures of 63–73.
Figure 10Structures of 74–87.
Figure 11Structures of 88–102.
Figure 12Structures of 103–116.
Figure 13Structures of 117–122.
Figure 14Structures of 123–132.
Figure 15Structures of 133–140.
Figure 16Structures of 141–152.
Figure 17Structures of 153–164.
Figure 18Structures of 165–181.
Figure 19Structures of 182–186.
Summary of source organisms, biological/pharmacological activities, compound numbers, and the cited references.
| Organisms | Biological/Pharmacological Activities | Compound | Reference |
|---|---|---|---|
|
| |||
|
| |||
|
|
| [ | |
|
| [ | ||
|
| |||
|
| [ | ||
|
| |||
| [ | |||
|
| |||
|
|
| [ | |
|
| [ | ||
|
| [ | ||
|
| |||
| Anti-Zika virus | [ | ||
| Anti-influenza A virus (H1N1) |
| [ | |
| Anti-hepatitis C virus |
| [ | |
| Anti-hepatitis C virus | [ | ||
|
| |||
| 22Rv1, PC-3, and LNCaP | [ | ||
| Hep G2, HT29, HCT116, A549, A375, MCF7 and U251 |
| [ | |
| MDA-MB-435, SGC-7901,A549 | [ | ||
|
| |||
|
| iNOS inhibitory activity | [ | |
| Inhibit secretion of 1L-1β by THP-1 cells | [ | ||
|
| |||
| promote triglyceride accumulation in 3T3-L1 |
| [ | |
| Inhibition of protein tyrosine | [ | ||
| phosphatases (PTPs) | [ | ||
| Inhibition of non-transmembrane PTPs (PTP1B) |
| [ | |
|
| |||
| increased a viability of paraquat-treated cells | [ | ||
|
| |||
| Pro-angiogenic activity in a vatalanib (PTK787)-induced vascular injury zebrafish model |
| [ | |
|
| |||
|
| |||
| [ | |||
| [ | |||
|
| [ | ||
|
| |||
|
| [ | ||
|
| |||
| MDA-MB-435, MDA-MB-231 NCI-H460, HCT-116, HepG2. MCF10A | [ | ||
|
| |||
|
| |||
|
| [ | ||
|
| [ | ||
|
| [ | ||
| [ | |||
|
| [ | ||
|
| [ | ||
|
| |||
| Anti-HIV activity | [ | ||
|
| |||
|
| HeLa | [ | |
| Human pancreatic cell lines: PANC-1, MIA PaCa-2, BxPC-3, ASPC-1 |
| [ | |
| A549, HT29, and MDA-MB-231 | [ | ||
| A549 and K562 | [ | ||
|
| |||
|
| Decrease dendritic cell secretion of pro-inflammatory cytokine IL-12p40 and anti-inflammatory cytokine IL-10 production | [ | |
|
| |||
|
| Increase adiponectin secretion during adipogenesis in hBM-MSCs | [ | |
|
| inhibitory activity against PTP1B | [ | |
|
| |||
|
| Antitrypanosomal activity against | [ | |
|
| |||
|
| Inhibitor of alkaline phosphatase |
| [ |
| Inhibit sortase A | [ | ||
|
| |||
|
| |||
|
| A2058, HT-29, MCF-7, MRC-5 | [ | |
|
| |||
|
| Decrease DC secretion of the pro-inflammatory cytokine IL-12p40 | [ | |
|
| |||
|
| |||
|
| [ | ||